Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
20

Inclusion Criteria

Subjects must be willing to not apply other treatment options for melasma during the course of the study
Subjects aged 18 years or older
Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
...
Subjects must be willing to not apply other treatment options for melasma during the course of the study
Subjects aged 18 years or older
Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
Subjects in general good health
Subjects must be willing and able to understand and provide informed consent for the use of their tissue and communicate with the investigator

Exclusion Criteria

Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
Subjects with a history of abnormal scarring
Subjects who have had a chemical peel in the past 3 months
...
Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
Subjects with a history of abnormal scarring
Subjects who have had a chemical peel in the past 3 months
Subjects who have used a prescribed retinoid in the past 3 months
Subjects with a history of abnormal wound healing
Subjects diagnosed with mental illness
Subjects who are pregnant and/or lactating
Subjects under 18 years of age
Subjects with a bleeding disorder
Subjects who are unable to understand the protocol or to give informed consent

Summary

Conditions
Melanosis
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Single Group Assignment
  • Masking: Single (Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Description

Participants in this study will be patients who are clinically diagnosed with at least a 2 x 2 cm patch of melasma on each side of their face (forehead or cheek). One half of the subject's face will be randomly selected to receive 4 treatments of 30% glycolic acid peels and the other half of the fac...

Participants in this study will be patients who are clinically diagnosed with at least a 2 x 2 cm patch of melasma on each side of their face (forehead or cheek). One half of the subject's face will be randomly selected to receive 4 treatments of 30% glycolic acid peels and the other half of the face will receive 4 treatments of 30% salicylic acid peels/ weeks 0, 4, 8, and 12. Follow up visit will be at week 16. This study is a pilot study designed to determine feasibility of these procedures.

Inclusion Criteria

Subjects must be willing to not apply other treatment options for melasma during the course of the study
Subjects aged 18 years or older
Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
...
Subjects must be willing to not apply other treatment options for melasma during the course of the study
Subjects aged 18 years or older
Subjects with at least a 2 x 2 cm patch of melasma on each side of the face (forehead or cheek)
Subjects in general good health
Subjects must be willing and able to understand and provide informed consent for the use of their tissue and communicate with the investigator

Exclusion Criteria

Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
Subjects with a history of abnormal scarring
Subjects who have had a chemical peel in the past 3 months
...
Subjects who have concurrent active uncontrolled disease to facial area (i.e uncontrolled acne)
Subjects with a history of abnormal scarring
Subjects who have had a chemical peel in the past 3 months
Subjects who have used a prescribed retinoid in the past 3 months
Subjects with a history of abnormal wound healing
Subjects diagnosed with mental illness
Subjects who are pregnant and/or lactating
Subjects under 18 years of age
Subjects with a bleeding disorder
Subjects who are unable to understand the protocol or to give informed consent

Tracking Information

NCT #
NCT01976286
Collaborators
Not Provided
Investigators
  • Principal Investigator: Murad Alam, MD Northwestern University
  • Murad Alam, MD Northwestern University